$RPRX · Royalty Pharma plc
Royalty Pharma reported Q3 2026 results: Portfolio Receipts rose 9% to $890M, Royalty Receipts up 9% to $883M, and Adjusted EBITDA up 8% to $840M. Net income attributable to Royalty Pharma plc fell to $145M from $284M a year earlier, driven by a $150M non-cash impairment on pelacarsen and higher interest/other expense. The company raised full-year 2026 Portfolio Receipts guidance to $3,500M-$3,550M, implying 10-11% Royalty Receipts growth.
- Portfolio Receipts rose 9% to $890M; Royalty Receipts up 9% to $883M.
- FY2026 Portfolio Receipts guidance raised to $3,500M-$3,550M from $3,400M-$3,500M.
- Net income attributable to Royalty Pharma fell to $145M from $284M on a $150M pelacarsen impairment.
- Repurchased 1.5M shares for $87M in Q3; 3.5M shares for $183M year-to-date.
- Announced $1.9B in new transactions and $1.6B capital deployment as of Nov 3, 2026.
Extended-hours trade at $67.12, up 1.09% vs the $66.40 regular close, signaling a mildly positive reaction to the guidance raise.
A guidance raise paired with a large impairment shows both the compounding power and the clinical risk embedded in Royalty Pharma's royalty portfolio.
Royalty Pharma's diversified royalty model continues to compound receipts even as individual assets like Promacta face generic erosion, underscoring the resilience of royalty aggregators versus single-product biotechs.
The $150M non-cash impairment on pelacarsen after its Phase 3 Lp(a)HORIZON trial missed its primary endpoint, plus Promacta's 75% decline on U.S. generic competition, highlight concentration and clinical-outcome risk across the portfolio.